Trade AKTS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Aktis Oncology, Inc. (AKTS) is trading at US$21.32, down 2.55% today as of Sep 21, 14:55 EDT. The company has a market capitalisation of US$1.34B. Over the past 52 weeks, AKTS has traded between US$14.72 and US$34.19. On Syfe you can trade AKTS with $0 commission and add it to your watchlist.
| Previous close | US$21.88 |
|---|---|
| Market cap | US$1.34B |
| 52-week range | US$14.72 – US$34.19 |
| Volume | 2.73M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
Year: 2026
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
Aug 19, 3:42 PM · MT Newswires
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target
Aug 19, 11:22 AM · MT Newswires
BMO Capital Initiates Akoustis Technologies at Outperform
Aug 19, 10:12 AM · MT Newswires
-- Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q2 Revenue $3.4M, vs. FactSet Est of $2.1M
Aug 13, 8:01 PM · MT Newswires
Aktis Oncology, Inc. (AKTS) stock is trading at US$21.32, -2.55% from the previous close of US$21.88.
The market cap for Aktis Oncology, Inc. (AKTS) stock is approximately US$1.34B.
The 52-week high for Aktis Oncology, Inc. (AKTS) stock is US$34.19.
The 52-week low for Aktis Oncology, Inc. (AKTS) stock is US$14.72.
Aktis Oncology, Inc. (AKTS) does not currently pay a dividend.
Stay on top of AKTS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
